From the "Don't expect critics to admit they were wrong about it" files: "Peer-reviewed hydroxychloroquine study finds 84% fewer hospitalizations among early treated outpatients
The anti-malaria drug hydroxychloroquine has been the subject of intense public debate after President Donald Trump championed it as a potential "game changer" in March just after the onset of the pandemic.
...
Zelenko and his co-authors claim that their research differentiates itself from other studies that have shown mixed or negative results for hydroxychloroquine by focusing on outpatients treated at an early stage of the disease.
...
"What differentiates this study is that patients were diagnosed very early with COVID-19 in an outpatient setting, and only high-risk patients were treated early on," Derwand said in a news release about the study.
...
"This is the first study with COVID-19 outpatients that shows how a simple-to-perform outpatient risk stratification allows for rapid treatment decisions shortly after onset of symptoms," Scholz added. "The well-tolerated 5-day triple therapy resulted in a significantly lower hospitalization rate and less fatalities with no reported cardiac side effects compared with relevant public reference data of untreated patients. The magnitude of the results can substantially elevate the relevance of early use, low-dose hydroxychloroquine, especially in combination with zinc.
...
Zelenko and his co-authors claim that their research differentiates itself from other studies that have shown mixed or negative results for hydroxychloroquine by focusing on outpatients treated at an early stage of the disease.
...
"What differentiates this study is that patients were diagnosed very early with COVID-19 in an outpatient setting, and only high-risk patients were treated early on," Derwand said in a news release about the study.
...
"This is the first study with COVID-19 outpatients that shows how a simple-to-perform outpatient risk stratification allows for rapid treatment decisions shortly after onset of symptoms," Scholz added. "The well-tolerated 5-day triple therapy resulted in a significantly lower hospitalization rate and less fatalities with no reported cardiac side effects compared with relevant public reference data of untreated patients. The magnitude of the results can substantially elevate the relevance of early use, low-dose hydroxychloroquine, especially in combination with zinc.